- Home
- ANL vs ATRA Comparison
ANL vs ATRA Comparison
Compare ANL & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- ATRA
- Stock Information
- Founded
- ANL 2004
- ATRA 2012
- Country
- ANL Cayman Islands
- ATRA United States
- Employees
- ANL N/A
- ATRA N/A
- Industry
- ANL
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANL
- ATRA Health Care
- Exchange
- ANL Nasdaq
- ATRA Nasdaq
- Market Cap
- ANL 62.4M
- ATRA 67.9M
- IPO Year
- ANL 2023
- ATRA 2014
- Fundamental
- Price
- ANL $1.68
- ATRA $12.34
- Analyst Decision
- ANL Hold
- ATRA Strong Buy
- Analyst Count
- ANL 1
- ATRA 3
- Target Price
- ANL N/A
- ATRA $21.00
- AVG Volume (30 Days)
- ANL 9.0K
- ATRA 50.8K
- Earning Date
- ANL 09-02-2025
- ATRA 08-11-2025
- Dividend Yield
- ANL N/A
- ATRA N/A
- EPS Growth
- ANL N/A
- ATRA N/A
- EPS
- ANL N/A
- ATRA 0.56
- Revenue
- ANL N/A
- ATRA $188,667,000.00
- Revenue This Year
- ANL N/A
- ATRA N/A
- Revenue Next Year
- ANL N/A
- ATRA N/A
- P/E Ratio
- ANL N/A
- ATRA $21.87
- Revenue Growth
- ANL N/A
- ATRA 202.41
- 52 Week Low
- ANL $1.10
- ATRA $5.01
- 52 Week High
- ANL $3.89
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ANL 55.77
- ATRA 60.31
- Support Level
- ANL $1.50
- ATRA $11.20
- Resistance Level
- ANL $1.99
- ATRA $12.09
- Average True Range (ATR)
- ANL 0.15
- ATRA 0.94
- MACD
- ANL 0.01
- ATRA -0.04
- Stochastic Oscillator
- ANL 43.82
- ATRA 92.66
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).